TABLE 3.
Primary method for assessment of liver fibrosis according to etiology of chronic liver disease
| Chronic liver disease | Liver biopsy | Fibroscan* | Fibrotest† | APRI, other simple biomarkers | Magnetic resonance elastography |
|---|---|---|---|---|---|
| Hepatitis C | 30 (37) | 43 (53.1) | 6 (7.4) | 2 (2.5) | 0 (0) |
| Hepatitis B | 26 (37.1) | 32 (45.7) | 6 (8.6) | 6 (8.6) | 0 (0) |
| HIV coinfection | 12 (36.4) | 15 (45.4) | 3 (9.1) | 3 (9.1) | 0 (0) |
| Nonalcoholic fatty liver disease | 38 (43.7) | 33 (37.9) | 5 (4.6) | 9 (1.1) | 2 (2.3) |
| Alcoholic liver disease | 34 (41) | 28 (33.7) | 4 (4.8) | 14 (16.9) | 3 (3.6) |
| Autoimmune/cholestatic liver disease | 58 (69) | 16 (19) | 2 (2.4) | 6 (7.2) | 2 (2.4) |
Data presented as n (%).
*
Echosens, France;
†
LabCorp, USA. APRI Aspartate aminotransferase-to-platelet ratio index